// App-Quantinova.ai

1745 : Application of BET/CBP/p300 multi-bromodomain inhibitors as a novel therapeutic strategy for MLL-rearranged acute lymphoblastic leukemia

Researchers

Presenter

  • Natsuki Imayoshi

Principal Investigators

  • Makoto Yoshioka

  • Shyh-Ming Yang

  • Koshi Akahane

  • Yuki Toda

  • Shigekuni Hosogi

  • Takeshi Inukai

  • Seiji Okada

  • David J. Maloney

  • Jefferey W. Strovel

  • Eishi Ashihara

Medical Centers

  • Kobe Pharmaceutical University, Kobe, Japan

  • ConverGene LLC, Gaithersburg, MD

  • National Institute of Health, Bethesda, MD

  • University of Yamanashi, Tokyo, Japan

  • Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan

Locations

  • Japan

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Hematological malignancies

  • Multiple Myeloma

  • Solid malignancies

Biomarkers

  • Breakpoint Cluster Region

  • CREB-binding protein

  • E1A Binding Protein P300

Drug/Treatment

  • Birabresib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved